Background
High-grade gliomas (HGGs) are the most common primary malignant brain tumors with a dismal prognosis [
1]. Few treatment options are available in HGGs at the time of recurrence which typically is local. Beneficial response to peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors has been observed in pilot studies including both low-grade (WHO grade II) and high-grade (WHO grade III and IV) gliomas [
2,
3]. Additionally, Heute et al. reported encouraging results with recurrent glioblastomas locally treated with
90Y-DOTATOC, with a complete remission in one patient [
4]. Therefore, PRRT remains an appealing treatment modality especially in recurrent HGGs. However, PRRT is technically demanding and careful selection of patients who are likely to respond is therefore required.
Somatostatin receptor (SSTR) expression in HGGs is controversial. While autoradiographic binding studies have shown no SSTR expression in glioblastomas, immunohistochemistry (IHC) and western blot have detected increased expression of subtypes SSTR
1, SSTR
2, and SSTR
3 [
5,
6]. Therefore, an
in vivo method to identify SSTR
2 expression, the most abundant subtype, in patients who are candidates for PRRT is required. While scintigraphic studies have shown variable uptake of octreotide analogs in gliomas, we are not aware of prospective studies on
68Ga-DOTANOC or
68Ga-DOTATOC uptake in gliomas with positron emission tomography (PET), which has superior sensitivity compared to scintigraphy in detecting SSTR
2-positive neuroendocrine tumors [
7,
8].
Our understanding on the genetic alterations in gliomas has led to the recognition of several molecular subtypes with distinct clinical, prognostic, and imaging characteristics [
9,
10].
IDH1 mutation,
MGMT promoter methylation, and 1p/19q co-deletion are the three molecular markers included today in routine assessment of gliomas due to their diagnostic, prognostic, or predictive value [
11]. An association between these molecular biomarkers and SSTR
2 expression in HGGs, however, has not been studied before.
We aimed to prospectively study the potential of 68Ga-DOTANOC and 68Ga-DOTATOC to target SSTR2 in HGGs and to detect HGGs suitable for PRRT in vivo. We hypothesized that SSTR2 expression in HGGs could be quantified with dynamic positron emission tomography/computed tomography (PET/CT) using 68Ga-DOTA-peptides. Also, our aim was to characterize SSTR2 expression in HGGs in relation to prognostic markers such as IDH1 mutation.
Methods
Twenty-seven patients with radiologically suspected primary (
n = 17) or recurrent (
n = 10) HGG scheduled for tumor resection between 2011 and 2013 were prospectively enrolled (mean age 52 years; 17 women and 10 men). PET/CT was performed prior to surgical resection with a mean interval of 19 days. Additionally, one patient with primary HGG was included in SSTR
2 IHC analysis without performing PET/CT.
68Ga-DOTANOC replaced
68Ga-DOTATOC as the tracer in practice after first three patients due to poor availability of the DOTATOC precursor. Patient characteristics are presented in Table
1. The study was approved by the Ethics Committee of the Hospital District of Southwest Finland and the Finnish Medicines Agency. All patients gave written informed consent before participation. The study has been registered at ClinicalTrials.gov (
NCT01460706).
Table 1
Clinical data, imaging abnormalities, and SSTR
2
expression
1 | 49/F | Primary | | III | A | | | 29.4 | 0.57 | TOC | 0.79 | −0.26 | 0 | 2 | B |
2 | 62/F | Primary | | III | A | | | 14.4 | 1.71 | NOC | 1.22b
| NA | 0 | 2 | B |
3 | 44/F | Primary | | III | A | | | 21.0 | 0 | NOC | −c
| − | 1 | 3 | B |
4 | 49/M | Primary | | III | A | | | 13.0 | 0 | NOC | − | − | 3 | 3 | C |
5 | 57/F | Primary | | III | A | 10.4 | | 12.5 | 0.16 | NOC | 0.69 | −0.47 | 0 | 0 | − |
6 | 18/M | Primary | | III | A | 10.9 | | 11.8 | 0 | NOC | − | − | 0 | 3 | B |
7 | 49/F | Primary | | III | A | | | 10.7 | 0.81 | NOC | 0.69 d
| NA | 1 | 3 | C |
8 | 32/F | Primary | | III | A | 8.4 | | 13.8 | 0 | X | X | X | 0 | 1 | C |
9 | 54/F | Primary | | III | O | 13.6 | | 27.7 | 0.03 | NOC | − | − | 3 | 3 | B |
10 | 60/M | Primary | | III | OA | | | 21.6 | 0 | NOC | − | − | 3 | 3 | B |
11 | 71/M | Primary | | IV | GBMO | 0 | 1.2 | | 1.91 | NOC | 3.07 | 1.41 | 0 | 3 | M |
12 | 37/M | Primary | | IV | GBMO | | | 21.0 | 4.32 | NOC | 0.99 | −0.62 | 3 | 3 | B |
13 | 35/F | Primary | | IV | GBM | 0 | 13.7 | | 1.27 | TOC | 0.65 | 0.39 | 0 | 1 | C |
14 | 63/F | Primary | | IV | GBM | 24.0 | | 24.1 | 12.2 | NOC | 2.21 | 0.98 | 0 | 0 | − |
15 | 62/F | Primary | | IV | GBM | 0 | 7.3 | | 11.5 | NOC | 3.01 | 1.26 | 0 | 0 | − |
16 | 67/F | Primary | | IV | GBM | 0 | 4.4 | | 14.8 | NOC | 1.62 | 0.36 | 0 | 1 | B |
17 | 70/M | Primary | | IV | GBM | 0 | 1.0 | | 21.5 | NOC | 2.85 | 1.80 | 0 | 3 | M |
18 | 76/F | Primary | | IV | GS | 0 | 0.9 | | 34.7 | NOC | 3.73 | 1.75 | 0 | 3 | M |
19 | 28/M | Recurrent | S | III | A | 81.2 | | 106.1 | 0 | NOC | − | − | 1 | 3 | B |
20 | 51/M | Recurrent | S, RT | III | O | 60.9 | | 253.7 | 0 | NOC | − | − | 3 | 3 | B |
21 | 42/F | Recurrent | S, S, RT, S | III | OA | 24.3 | 99.5 | | 0 | NOC | − | − | 3 | 3 | C |
22 | 46/M | Recurrent | S, RT, C | III | OA | 39.0 | 100.4 | | 28.2 | NOC | 5.68 | 3.33 | 1 | 1 | C |
23 | 42/F | Recurrent | S, CRT | IV | GBM | 24.0 | 37.1 | | 0.04 | TOC | 0.46 | −0.34 | 0 | 3 | B |
24 | 68/F | Recurrent | S, CRT | IV | GBM | 23.1 | 26.3 | | 27.9 | NOC | 2.40 | 1.57 | 0 | 0 | − |
25 | 64/F | Recurrent | S, CRT | IV | GBM | 34.2 | 38.2 | | 12.8 | NOC | 2.70 | 1.07 | 0 | 3 | B |
26 | 42/F | Recurrent | S, CRT | IV | GBM | 5.5 | 13.6 | | 28.0 | NOC | 2.44 | 2.28 | 0 | 3 | B |
27 | 61/F | Recurrent | S, RT | IV | sGBM | 16.1 | 21.3 | | 2.59 | NOC | 1.98 | 0.64 | 0 | 2 | C |
28 | 57/M | Recurrent | S, CRT | IV | GBM | 11.0 | 27.5 | | 3.03a
| NOC | 3.26 | 2.33 | 0 | 3 | B |
PET/CT with 68Ga-DOTA-peptides and MRI
68Ga-DOTA-peptides were synthesized as previously described [
12]. Radiochemical purity and specific activity (mean) was 99.9% and 31.5 GBq/μmol for
68Ga-DOTANOC, and 96.5% and 26.8 GBq/μmol for
68Ga-DOTATOC, respectively. PET/CT of the brain was performed using a GE Discovery VCT PET/CT Scanner (General Electric Medical Systems, Pewaukee, WI, USA). Dynamic PET was acquired over 60 min (8 × 15-, 6 × 30-, 5 × 180-, 4 × 300-, and 2 × 600-s frames) after intravenously injected
68Ga-DOTANOC (123 MBq, median) or
68Ga-DOTATOC (130 MBq, median). Low-dose CT (120 kV, 10 to 95 mA, noise index 25, slice thickness 3.75 mm) was used for attenuation correction. PET images were reconstructed (256 × 256 matrix, OSEM3D, 3 iterations, 28 subsets, 4.8-mm Hanning postfilter) yielding a pixel size of 1.4 mm. A duration of 60 min was determined after 90-min dynamic PET performed to one patient (no. 13) and 5-min static scans performed to three patients (nos. 11, 12, and 23) 96 min post-injection confirmed that tumor uptake did not increase after 60 min.
Clinical preoperative MRI nearest in time to PET scan (mean interval 14 days) was employed, and post-contrast T1-weighted images (MRI-T1-Gad) were used to define the tumor volume with contrast enhancement. MRI scanners and parameters used are listed in Online Resource 1.
Image evaluation
Analyses were performed using in-house developed software (Carimas 2.7;
http://www.turkupetcentre.fi/carimas/). PET and MRI-T1-Gad images were co-registered, and spherical volumes of interest (VOIs) were manually placed over the tumor area with maximum activity. VOIs for contralateral normal brain white matter, nasal mucosa, pituitary gland, and skin of the occiput were also defined, and maximum standardized uptake values (SUVmax) were calculated (SUV = [Tissue radioactivity concentration (Bq/ml) × Body weight (g)]/Injected dose (Bq)). Tumor mean SUVmax 30 to 60 min post-injection was used for further analyses.
Logan plot with skin as a reference tissue was used for tracer kinetic modeling [
13]. We used 5 min as the starting point for linear regression model that was optimized against the normalized tumor and reference tissue time-activity curves (TAC), with the slope being the distribution volume ratio (DVR). Binding potential (BP) corresponds to the density of available receptors and is calculated as BP = DVR − 1.
For comparison of tumor volume abnormalities in PET and MRI-T1-Gad, the images were co-registered by automatic fusion using iPlan RT Treatment Planning Software (Brainlab, Munich, Germany). Tumor PET volumes were contoured with a threshold of 40% SUVmax (V
PET). Contrast-enhanced tumor volume in MRI-T1-Gad (V
T1-Gad) was delineated by thresholding the enhancing tumor volume on visual basis and then manually subtracting the hyperintense volume on precontrast T1-weighted images. Overlapping volumes between V
PET and V
T1-Gad were determined, and Dice similarity coefficient (DC = [2 × Intersection]/[V
PET + V
T1-Gad]) was calculated. A DC value of 1 indicates perfect similarity between the volumes, while a value of 0 indicates no similarity. Patient no. 5 was excluded from analysis due to low SUVmax following failure in PET volume delineation.
Immunohistochemistry and molecular markers
Formalin-fixed paraffin-embedded tumor tissues were sectioned at 3 μm and used for analyses. Antibodies for IHC are listed in Table
2.
MGMT promoter methylation was studied by pyrosequencing [
14], 1p/19q co-deletion by fluorescent
in situ hybridization, and
EGFR amplification by silver
in situ hybridization [
15].
Table 2
Primary antibodies and methods used for immunohistochemistry
SSTR2
| UMB-1 | Abcam, Cambridge, UK | Ventana Benchmark XT Autostainer (Ventana Medical Systems, Strasbourg, France) |
ultraVIEW Universal Detection Kit (Ventana, Strasbourg, France) |
SSTR3
| Rabbit polyclonal (ab28680) | Abcam, Cambridge, UK | Labvision Autostainer (Thermo Scientific Inc, Kalamazoo, MI) | BrightVision Detection Kit (Immunologic, Duiven, the Netherlands) |
SSTR5
| Rabbit polyclonal (AB5681) | Millipore, Billerica, MA | Labvision Autostainer | BrightVision Detection Kit |
EGFR | 5B7 | Ventana, Strasbourg, France | Ventana Benchmark XT Autostainer |
ultraVIEW Universal Detection Kit |
IDH1 R132H | H09 | Dianova, Hamburg, Germany | Ventana Benchmark XT Autostainer |
ultraVIEW Universal Detection Kit |
CD68 | PG-M1 | Dako, Glostrup, Denmark | Ventana Benchmark XT Autostainera
|
ultraVIEW Universal Detection Kit + Universal Alkaline Phosphatase Red Detection Kit (Ventana)a
|
Ki67 | 30-9 | Ventana, Strasbourg, France | Ventana Benchmark XT Autostainer |
ultraVIEW Universal Detection kit |
SSTR2 IHC was scored first independently by an experienced neuropathologist (MG) and finally in consensus with a second observer (AK) both blinded to PET data. Double staining with UMB1 + CD68 was used to exclude SSTR2 staining in microglia and macrophages and to evaluate the number of these cells in the tumor specimen by counting all CD68-positive cells and tumor cells in one representative high-power field. In diffuse gliomas, HE staining and IHC for IDH1 mutation assisted in localizing tumor cells. Three scoring parameters were reported for SSTR2 staining: the highest (minimum 10% of tumor area), the most common staining intensity, and the localization of staining (membranous, cytoplasmic, or both). Staining intensities were classified as follows: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The same scoring parameters were used for EGFR IHC. SSTR2 IHC was further categorized as positive if the sum of the highest and most common staining intensities was ≥4 and negative if the sum was <4.
Statistical analysis
Data are presented as mean ± SD. Pearson or Spearman’s rank correlations were used between tracer uptake parameters and V
T1-Gad. V
PET and V
T1-Gad were compared with Mann–Whitney U test. The association between SSTR2 status and molecular markers was studied with Pearson chi-square analysis by cross-tabulations, and difference in Ki67 with independent samples t test. SSTR2 IHC and tracer uptake were compared with Kruskal-Wallis. Kaplan-Meier curves with log-rank test and univariate Cox regression were used to analyze progression-free survival (PFS) and overall survival (OS). Multivariate Cox regression (backward Wald) was performed for PFS with SSTR2 status and tumor grade as variables. PFS was defined as the time from the first surgical resection (also for recurrent HGGs) to the first tumor progression in MRI, deterioration in clinical symptoms, or end of follow-up. OS was defined as the time from the first surgical resection to death or end of follow-up. Two-tailed P values <0.05 were regarded significant. Statistical analyses were conducted using SPSS 21 for Mac (SPSS Inc., Chicago, IL, USA).
Discussion
We have demonstrated that 68Ga-DOTA-peptide uptake in PET/CT is associated to disrupted BBB but does not correlate to immunohistochemically (IHC) determined SSTR2 status, suggesting limited benefit of this approach in defining suitable patients for PRRT. Low tumor SUVmax further implies that the achievable dose with intravenously administered PRRT remains low. The second finding of particular interest was the positive association between SSTR2 expression and IDH1 mutation, oligodendroglioma component, and improved PFS, which indicates that SSTR2 expression may become a new biomarker in HGG useful for prognostication and therapeutic decision-making.
Our findings correspond to SSTR scintigraphic studies in low- and high-grade gliomas where
111In-DTPA-D-Phe1-octreotide scintigraphy visualized the tumors with disrupted BBB but did not correlate to
in vitro SSTR autoradiography [
16]. The authors reasoned that this discrepancy was due to nonspecific accumulation and trapping of the octreotide molecules. Again, we did not find a correlation between
68Ga-DOTA-peptide uptake and SSTR
2 IHC, which may be related to the heterogeneity of tumor tissue and uncertainties in obtaining the tissue sample from regions with the highest tracer uptake. Our results, however, do not confirm that the uptake is merely due to nonspecific accumulation. First, variation in SUVmax was noticed among similar MRI-T1-Gad volumes (Figure
1C). Second, alteration in BP values (range −0.62 to 3.33) suggests different SSTR
2 densities in HGGs. Third, the Dice similarity coefficient between tumor volumes in PET and MRI-T1-Gad was rather low (0.41), implicating discordance between these volumes. In other words, tracer uptake was not limited to the area of disrupted BBB but was present in neighboring areas due to diffusion and/or receptor binding. Of note is also low expression of SSTR
3 and SSTR
5 which did not explain differences in tracer uptake. By contrast, specific binding is not supported by the time course of tumor
68Ga-DOTA-peptide uptake (Figure
1A) as the typical pattern of ligand-binding curve is not present. Thus, nonspecific tracer uptake cannot be excluded since a blocking study requiring another dynamic PET/CT was not performed.
The magnitude of diagnostic radionuclide uptake is not trivial for a successful PRRT. In meningiomas treated with PRRT, SUVmax with
68Ga-DOTA-peptides was related to the corresponding
177Lu-labeled radionuclide uptake and therapeutic dose [
17]. SUVmax in meningiomas ranged from 4.3 to 68.7 with a very low therapeutic dose achieved with the lowest SUVmax. In our study, mean SUVmax was 2.25 with only four GBMs and one anaplastic glioma demonstrating SUVmax >3.0, suggesting an insufficient achievable dose in PRRT. It has to be noted, though, that PRRT in extra-axial meningiomas is intravenously delivered whereas in gliomas invading the brain, the therapeutic radionuclide needs to be locally injected [
2-
4]. This is of importance especially in HGGs with intact BBB that are SSTR
2 positive but lack tracer uptake in PET. These tumors may benefit from locally delivered PRRT, which, however, cannot be evaluated by intravenously given
68Ga-DOTA-peptides.
To our knowledge, this study demonstrates for the first time that high SSTR
2 expression in HGG is associated with
IDH1 mutation which is regarded as the most powerful prognostic marker for a favorable outcome compared to
IDH1 wild-type gliomas [
18]. It is unclear, however, why
IDH1 mutation affects prognosis and what the interaction with other markers is. Recently,
IDH1 mutation was found to determine the prognostic and predictive value of
MGMT promoter methylation in anaplastic gliomas [
19]. Association with mutant
IDH1 implicates a potential role for SSTR
2 in the favorable outcome of chemosensitive and radiosensitive HGGs. This is substantiated by the observed trend of correlation between SSTR
2 expression and
MGMT promoter methylation.
Previous studies have not detected a clear association between SSTR
2 expression and oligodendroglioma component. Cervera et al. found increased SSTR
2 mRNA in oligodendrogliomas but finally concluded that it was due to contamination from normal brain [
20]. Our SSTR
2 scoring was based on IHC with a well-documented monoclonal antibody UMB-1 allowing cellular localization [
21]. We found that SSTR
2 staining was not restricted to oligodendroglial tumor cells but was similarly present in astrocytic cells in mixed oligoastrocytomas. Furthermore, two anaplastic oligodendrogliomas out of the four HGGs with 1p/19q co-deletion, a biomarker strongly linked to oligodendroglial histology [
22], also showed the most intensive SSTR
2 staining. We thus demonstrate an association between SSTR
2 and oligodendroglioma component but underline that a larger study is necessary to confirm this initial finding.
SSTR
2 status was an independent prognostic marker for PFS after adjustment to glioma grade. SSTR
2 expression has previously been associated to improved survival with neuroendocrine tumors [
23] and childhood neuroblastomas [
24], suggesting a potential role for SSTR
2 as a tumor suppressor. In fact, this antitumor effect has been demonstrated in experimental pancreatic tumors stably expressing SSTR
2 [
25], or after therapeutic SSTR
2 gene transfer [
26] with inhibited tumor growth. Our results on improved PFS substantiate the anti-oncogenic role of SSTR
2 in HGGs as well.
Our study confronts limitations. First, two tracers with different affinity profiles for SSTR subtypes were used. However, the highest affinity with both
68Ga-DOTANOC and
68Ga-DOTATOC is for SSTR
2 [
27]. In addition, our HGG samples demonstrated minimal expression of subtypes SSTR
3 and SSTR
5, for which
68Ga-DOTANOC possesses higher affinity compared to
68Ga-DOTATOC. Also, as
68Ga-DOTATOC was applied only in 3 patients and
68Ga-DOTANOC in 24 patients, we conclude that most likely this limitation had little effect on the outcome. Second, the number of patients was limited. Our data on established biomarkers, however, was in accordance with current literature giving substantiation also to our SSTR
2 results. Third, potential alteration in tumor edema affecting volumetric analyses due to differences in steroid dosing during the interval between MRI and PET/CT cannot be excluded. Furthermore, clinical MRI with different scanners and parameters was used for MRI-T1-Gad evaluation.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK participated in the study setup and PET/CT scannings, analyzed the data, and drafted the manuscript. MG carried out the histopathologic studies, analyzed the data, and contributed to manuscript drafting. JF and VV contributed to the collection of data and coordination of the study. RP, MP, SS, JJ, and JK contributed to the analysis and interpretation of the imaging data. TT contributed to the setup of PET/CT scannings and evaluation of the data, and PL to the setup of tracer production. AR participated in the design of the study and in the procedure of tracer setup. HM conceived the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.